Anaptysbio, Inc. · NASDAQ:ANAB
Anaptysbio — Technical Presentation (March 2018)
16 slides from Anaptysbio's technical presentation, Mar 26, 2018
Slide 1: Anti-IL-33 (ANB020) Phase 2a Peanut Allergy Interim Data Update
NASDAQ: ANAB Anti-IL-33 (ANB020) Program Phase 2a Peanut Allergy Clinical Trial Interim Data Update March 26th 2018 Exhibit 99.2
Slide 2: Safe Harbor Statement
Safe Harbor Statement This presentation and the accompanying oral presentation contain “forward‐looking” statements that are based on our management’s beliefs and assumptions and on information currently available to management. Forward‐looking statements include all statements other than statements
Slide 3: AnaptysBio: Clinical-Stage Antibody Development Company
AnaptysBio: Clinical-Stage Antibody Development Company Focused on Novel Antibody Medicines for Severe Inflammatory Diseases TESARO Celgene Rapid Antibody Generation Platform Technology ~2.5 years Antibody Discovery Preclinical & Translational IND or Equivalent Filing Antibody Medicines For Severe D
Slide 4: Pipeline programs and anticipated milestones
Program Therapeutic Indication Development Stage & Anticipated Milestones Commercial Rights Discovery Preclinical Phase 1 Phase 2 Phase 3 ANB020: Anti-IL-33 Moderate-to-Severe Adult Atopic Dermatitis Phase 2a Data Presented at AAD February 2018 Phase 2b To Be Initiated In H1 2018 Moderate-to-Severe
Slide 5: Wholly-Owned Pipeline: Anti-IL-33 (ANB020)
Wholly-Owned Pipeline: Anti-IL-33 (ANB020) Moderate-to-Severe Adult Atopic Dermatitis Moderate-to-Severe Baseline Adult Peanut Allergy Severe Adult Eosinophilic Asthma
Slide 6: Atopic Diseases: Large Unmet Medical Need
Atopic Diseases: Large Unmet Medical Need IL-33-driven Disease Mechanism Affects Multiple Organ Systems Skin Digestive Tract Lung Inflammatory Response to Allergen Atopic Dermatitis 1.4 million adult atopic dermatitis patients in the US Estimate ~280,000 adults with moderate-to-severe atopic dermati
Slide 7: ANB020: First-in-Class Anti-IL-33 Antibody Broadly Applicable to Atopic Diseases
ANB020: First-in-Class Anti-IL-33 Antibody Broadly Applicable to Atopic Diseases IL-33 is an upstream driver of atopic disease Human genetics validate key role of IL-33 in atopic dermatitis and asthma Pro-inflammatory cytokine released upon allergen contact with epithelium Activates downstream relea
Slide 8: ANB020 Phase 2a Trials
ANB020 Phase 2a Trials Indication Trial Design Clinical Endpoint Data Readout Moderate-to-Severe Adult Atopic Dermatitis 12 patients, all dosed with placebo followed by single dose of ANB020 Eczema Area & Severity Index (EASI) Top-line data announced October 2017 Detailed data presented at AAD Febru
Slide 9: ANB020 Peanut Allergy Phase 2a Clinical Trial design
Enrolled 20 adult peanut allergy patients with a history of anaphylaxis Blinded, placebo-controlled oral food challenge (OFC) evaluated peanut tolerance at Baseline OFC and Day 14 OFC in accordance with PRACTALL guidelines Each OFC limited to a maximum tested cumulative peanut dose of 500mg Patients
Slide 10: Enrolled Patient Characteristics
Enrolled Patient Characteristics Interim Analysis Focused on Moderate-to-Severe Baseline Patients We believe peanut allergy patients with moderate-to-severe baseline symptoms represent an unmet medical need Characteristic All Patients Moderate-to-Severe Baseline Patients* N 20 16 Average Age 30 31 A
Slide 11: Top-Line Proof-of-Concept Data
Top-Line Proof-of-Concept Data 46% ANB020 Dosed vs 0% Placebo Dosed Patients With Moderate-to-Severe Baseline Symptoms Improved Peanut Tolerance to Maximum Tested Cumulative Dose of 500mg Improved peanut tolerance to cumulative 500mg at Day 14 OFC Improved peanut tolerance to cumulative 500mg and im
Slide 12: Lower Incidence of Concomitant Allergy Symptoms in ANB020 Dosed Patients
Lower Incidence of Concomitant Allergy Symptoms in ANB020 Dosed Patients 4 of 5 (80%) Placebo vs 1 of 15 (7%) ANB020 Dosed Patients Presented With Allergic Symptoms Peanut allergy is associated with other allergic conditions, such as atopic dermatitis and asthma, which can lead to concomitant allerg
Slide 13: Favorable ANB020 Safety Profile In Peanut Allergy Patients
Favorable ANB020 Safety Profile In Peanut Allergy Patients No Serious Adverse Events Or Dropouts Reported Most frequently reported adverse events to date were: Headache in 4 of 15 patients dosed with ANB020, 3 mild cases and 1 moderate case Mild and moderate cases of allergy-related events occurring
Slide 14: Proof-of-concept data summary and conclusions
Proof-of-concept data illustrates response in adult peanut allergy patients with moderate-to-severe baseline symptoms after a single dose of ANB020 Day 14 readout supports potential for rapid patient benefit Potential to further improve peanut tolerance with multiple doses Concomitant allergy sympto
Slide 15: AnaptysBio: Clinical-Stage Antibody Development Company
AnaptysBio: Clinical-Stage Antibody Development Company Focused on Novel Antibody Medicines for Severe Inflammatory Diseases TESARO Celgene Rapid Antibody Generation Platform Technology ~2.5 years Antibody Discovery Preclinical & Translational IND or Equivalent Filing Antibody Medicines For Severe D
Slide 16: AnaptysBioW Ve
AnaptysBioW Ve